ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Charts Near-Term Rebound With Emerging Momentum
Commercial traction for neffy and a WMDST valuation labeling the stock under-valued create a constructive backdrop; technical signals point to early-stage bullish pressure while price structure still faces material moving-average resistance.









